Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGY) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Shandong Weigao Group Medical Polymer Co Cash Conversion Cycle Related Terms
Shandong Weigao Group Medical Polymer Co Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co Cash Conversion Cycle Chart
Shandong Weigao Group Medical Polymer Co Annual Data
SHWGY vs ISRG, BDX, MDLN: Cash Conversion Cycle Comparison
For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Group Medical Polymer Co Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Group Medical Polymer Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Shandong Weigao Group Medical Polymer Co's Cash Conversion Cycle falls into.
Shandong Weigao Group Medical Polymer Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co (SHWGY) has a Cash Conversion Cycle of 156.22 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors.
Is Shandong Weigao Group Medical Polymer Co's Cash Conversion Cycle too high?
Shandong Weigao Group Medical Polymer Co's current Cash Conversion Cycle is 156.22. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Shandong Weigao Group Medical Polymer Co's value of 156.22 is 0.5% below this industry median. Overall, Shandong Weigao Group Medical Polymer Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Group Medical Polymer Co's Cash Conversion Cycle compare to ISRG and BDX?
Shandong Weigao Group Medical Polymer Co's Cash Conversion Cycle of 156.22 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Shandong Weigao Group Medical Polymer Co's value of 156.22 is 0.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Group Medical Polymer Co's current Cash Conversion Cycle of 156.22 is 0.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Group Medical Polymer Co's current Cash Conversion Cycle is 156.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Group Medical Polymer Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co (SHWGY) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.04, compared to a current price of $1.60 — trading 47.5% below its estimated fair value. The current Cash Conversion Cycle is 156.22 and 0.5% below the Medical Devices & Instruments industry median of 156.96. Shandong Weigao Group Medical Polymer Co's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Shandong Weigao Group Medical Polymer Co (SHWGY), the current Cash Conversion Cycle is 156.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Weigao Group Medical Polymer Co (SHWGY) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co stock appears to be undervalued.
The current stock price of $1.60 is trading 47.5% below its estimated GF Value™ of $3.04.
GuruFocus considers Shandong Weigao Group Medical Polymer Co to be Significantly Undervalued.
Key valuation signals for SHWGY:
Cash Conversion Cycle: 156.22
GF Value™: $3.04 vs. price of $1.60 (47.5% below fair value)
Industry Position: 0.5% below the Medical Devices & Instruments median
No single metric tells the full story. See the SHWGY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Weigao Group Medical Polymer Co Business Description
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.
70GF Score
Get the complete analysis for SHWGY
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHWGY has been successfully added to your 
